The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: Results from a randomized, double-blind, trial

AIDS

Volumn 14, Issue 7, 2000, Pages 781-789

  Katlama, Christine ^a   Clotet, Bonaventura ^b   Plettenberg, Andreas ^c   Jost, Josef ^d   Arasteh, Keikawus ^e   Bernasconi, Enos ^f   Jeantils, Vincent ^g   Cutrell, Amy ^h   Stone, Chris ⁱ   Ait Khaled, Mounir ⁱ   Purdon, Scott ⁱ  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e Vivantes Auguste Viktoria Klinikum   (Germany)

^f Ospedale Civico Lugano   (Switzerland)

^g HÔPITAL JEAN VERDIER   (France)

^h GLAXOSMITHKLINE   (United States)

ⁱ GLAXOSMITHKLINE   (United Kingdom)

Author keywords

1592U89; Abacavir; ABC; AIDS; Antiretroviral experienced; Combination therapy; HIV; Lamivudine; M184V; Ziagen

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SLEEP DISORDER; VOMITING;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DOUBLE-BLIND METHOD; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034069732     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200005050-00003     Document Type: Article

References (11)

1. 1. Daluge SM, Good SS, Faletto MB, et al. 1592U89, a novel carbocyclic nucleoside analogue with potent, selective antihuman immunodeficiency virus activity. Antimicrob Agents Chemother 1997, 41:1082-1093.
2. 2. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997, 41:1094-1098.
3. 3. Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS 1998, 12:F203-F209.
4. 4. Torres R, Saag M, Lancaster D, et al. Antiviral effects of abacavir (1592) following 48 weeks of therapy. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 659].
5. 5. Lanier ER, Stone C, Griffin, P, Thomas D, LaFon S. Phenotypic sensitivity to Abacavir (1592, ABC) in the presence of multiple genotypic mutations: correlation with viral load response. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 686].
6. 6. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 4: 269(5224):696-699.
7. 7. Hertogs K, de Bethune M-P, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998, 42:269-276.
8. 8. Solo Power Analysis. BDMP Statistical Software Inc.; 1991: 153-158.
9. 9. Fleiss JL. Statistical Methods for Rates and Proportions. Wiley and Sons; 1981.
10. 10. Nijhius M, Schuurman R, De Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997, 176:398-405.
11. 11. Harrigan, PR, Kinghorn, I, Bloor, et al. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for AZT susceptibility. J Virol 1996, 70:5930-5934.